Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 9/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2413779 | 0.80 | NPC1 (0.45) | TERTCNR2MAPTCNR1 | |
| SCHEMBL19068348 | 0.79 | PDK2 (0.43) | CNR2ALDH1A1MAPTSSTR4PDCD1LG2 | |
| SCHEMBL27887573 | 0.75 | POLB (0.44) | CNR2MAPTPDCD1LG2CD274HTR1A | |
| SCHEMBL2411441 | 0.74 | HTR1A (0.33) | CNR2CNR1PDCD1LG2CD274HTR1A | |
| SCHEMBL24664635 | 0.74 | CCR1 (0.41) | CCR1TERTCNR2ALDH1A1CNR1 | |
| SCHEMBL27904377 | 0.73 | CNR2 (0.47) | CNR2CNR1 | |
| SCHEMBL22144706 | 0.73 | PDK2 (0.39) | CNR2ALDH1A1MAPTSSTR4PDCD1LG2 | |
| SCHEMBL2414945 | 0.73 | CD274 (0.35) | PDCD1LG2CD274 | |
| SCHEMBL17090735 | 0.73 | CD274 (0.35) | PDCD1LG2CD274 | |
| SCHEMBL2414941 | 0.73 | CD274 (0.35) | PDCD1LG2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2921489-B1 | 2-PYRIDONE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2921489-B1 | 2-PYRIDONE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-9695148-B2 | 2-pyridone compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9695148-B2 | 2-pyridone compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9695148-B2 | 2-pyridone compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-07-04 | — | — | US | disclosed |
| CN-104768944-B | 2 pyridinone compounds | 日产化学工业株式会社 | 2017-03-29 | — | — | CN | disclosed |
| US-20160289208-A1 | 2-PYRIDONE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-06 | — | — | US | disclosed |
| US-20160289208-A1 | 2-PYRIDONE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-06 | — | — | US | disclosed |
| US-20160289208-A1 | 2-PYRIDONE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-06 | — | — | US | disclosed |
| CN-102884047-B | 2-pyridone compounds | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-11-25 | — | — | CN | disclosed |
| EP-2921489-A1 | 2-PYRIDONE COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-09-23 | — | — | EP | disclosed |
| EP-2921489-A1 | 2-PYRIDONE COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-09-23 | — | — | EP | disclosed |
| CN-104768944-A | 2-pyridone compound | TAISHO PHARMACEUTICAL CO LTD | 2015-07-08 | — | — | CN | disclosed |
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| WO-2014077235-A1 | 2-PYRIDONE COMPOUND | 大正製薬株式会社 (JP) | 2014-05-22 | — | — | WO | disclosed |
| CN-102884047-A | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO LTD | 2013-01-16 | — | — | CN | disclosed |
| EP-2508513-A1 | 2-PYRIDONE COMPOUNDS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | PDXK, HK1, KCNJ2 | CCR1 4117/4885TERT 1645/4885CNR2 825/4885 |
| US-20160289208-A1 | 2-PYRIDONE COMPOUND | PDXK, MAP4K5, P2RY2 | CCR1 4709/4885TERT 2421/4885CNR2 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.